Thrombolytic and newer mechanical device treatment for acute ischemic stroke

Expert Review of Neurotherapeutics

Volumn 6, Issue 7, 2006, Pages 1099-1105

  Lutsep, Helmi L ^a,b  

^a Oregon Poison Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Acute stroke treatment; Device; Intra arterial; Mechanical thrombolysis; Merci Retriever; Stroke; Tissue plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CATHETER; DEVICE; DOSE RESPONSE; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; INFORMATION RETRIEVAL; NUCLEAR MAGNETIC RESONANCE; RECANALIZATION; REVIEW; THROMBECTOMY; TREATMENT OUTCOME;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HUMANS; INJECTIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; THROMBECTOMY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33745956112     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.7.1099     Document Type: Review

References (23)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1587 (1995). Trial leading to first approved acute stroke treatment.
2. Becker KJ, Brott TG. Approval of the MERCI clot retriever: a critical review. Stroke 36, 400-403 (2005).
3. Haley EC Jr, Lewandowski C, Tilley BC, NINDS rt-PA Stroke Study Group. Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann. Emerg. Med. 30, 676-682 (1997).
4. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283, 145-150 (2000).
5. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172, 1307-1312 (2005).
6. Heuschmann PU, Berger K, Misselwitz B et al. The German Stroke Registers Study Group and for the competence net stroke. Frequency of thrombolytic therapy in patients with acute ischemic stroke and risk of in-hospital mortality. Stroke 34, 1106-1113 (2003).
7. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282, 2019-2026 (1999).
8. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363, 768-774 (2004).
9. Ribo M, Molina CA, Rovira A et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36, 602-606 (2005).
10. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28, 2119-2125 (1997).
11. Smith WS, Sung G, Starkman S et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36, 1432-1440 (2005). Study upon which clearance of the Merci Retriever was based.
12. Furlan A, Higishida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282, 2003-2011 (1999). Study providing the historical control against which current intra-arterial treatment of stroke is compared.
13. Gobin YP, Starkman S, Duckwiler GR et al. MERCI 1: a Phase I study of mechanical embolus removal in cerebral ischemia. Stroke 35, 2848-2854 (2004).
14. Multi-MERCI Writing Committee for the Multi-MERCI Investigators. Safety of mechanical thrombectomy and intravenous t-PA in acute ischemic stroke. Results of the Multi-MERCI trial, Part I. Am. J. Neuroradiol. (2006) (In press).
15. Berlis A, Lutsep H, Barnwell S et al. Mechanical thrombolysis in acute ischemic stoke with EPAR (Endovascular Photoacoustic Recanalization). Stroke 35, 1112-1116 (2004). First mechanical thrombolysis treatment trial in acute stroke to be published.
16. Ribo M, Alvarez-Sabin J, Montaner J et al. Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke 37, 1000-1004 (2006).
17. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59, 862-867 (2002).
18. The IMS Investigators. Preliminary results of IMS II Trial. Stroke 37, 708 (2006).
19. Mahon BR, Nesbit GM, Barnwell SL et al. North American clinical experience with the EKOS microlysis infusion catheter for the treatment of embolic stroke. Am. J. Neuroradiol. 24, 534-538 (2003).
20. Alexandrov AV, Moline CA, Grotta JC et al. The CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 351, 2170-2178 (2004).
21. Daffertshofer M, Gass A, Ringleb P et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator. Results of a Phase II clinical trial. Stroke 36, 1441-1446 (2005).
22. Lees KR, Zivin JA, Ashwood T et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588-600 (2006).
23. Adams RJ, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke 34, 1056-1083 (2003)